Therapy for Crohn disease
Therapy for Crohn disease
复制标题
克罗恩病的治疗
DOI：
10.1097/00001574-200007000-00005
复制
发表时间：
2000
影响因子：
2.5
通讯作者：
W. Sandborn
中科院分区：
文献类型：
--
作者：
W. Sandborn
克罗恩病的药物治疗进展缓慢：继续报道美沙拉嗪的小型非确定性对照试验，但结果不足以改变大型荟萃分析的结论，该分析显示美沙拉嗪在克罗恩病中仅具有边际获益。低剂量、回肠控释布地奈德对预防克罗恩病术后复发无效。负荷剂量的硫唑嘌呤静脉注射不会加速接受类固醇治疗的克罗恩病患者的反应时间;然而，标准硫唑嘌呤可能比以前报道的更快起作用。吗替麦考酚酯在治疗活动性克罗恩病方面可能与硫唑嘌呤等效。口服甲氨蝶呤（15 mg/周）治疗活动性克罗恩病有获益的趋势，接受甲氨蝶呤（15或25 mg/周）皮下给药的炎症性肠病患者的甲氨蝶呤血药浓度无显著差异。一项初步研究的结果表明，他克莫司可能会关闭克罗恩病患者的肛周瘘。抗肿瘤坏死因子抗体英夫利西单抗可有效闭合克罗恩病患者的肛周瘘和肠外瘘，并维持缓解。英夫利西单抗也导致内镜和组织学缓解。皮下注射重组白细胞介素-11治疗活动性克罗恩病有获益的趋势。两项初步研究表明，沙利度胺可能对难治性克罗恩病患者有益。
Medical therapy for Crohn disease has advanced incrementally: Small, nondefinitive controlled trials of mesalamine continue to be reported, but the results are not sufficient to change the conclusion of a large meta-analysis that shows only marginal benefit of mesalamine in Crohn disease. Low-dose, controlled ileal-release budesonide is not effective for preventing postoperative recurrence of Crohn disease. A loading dose of intravenous azathioprine does not accelerate the time to response in patients with steroid-treated Crohn disease; however, standard azathioprine may work more quickly than previously reported. Mycophenolate mofetil may be therapeutically equivalent to azathioprine for active Crohn disease. There is a trend toward benefit of oral methotrexate (15 mg/wk) for active Crohn disease, and there is no significant difference in the blood concentrations of methotrexate in patients with inflammatory bowel disease who receive methotrexate (15 or 25 mg weekly) administered subcutaneously. Results in a pilot study suggest that tacrolimus may close perianal fistulas in patients with Crohn disease. The anti-tumor necrosis factor antibody infliximab is effective in closing perianal and enterocutaneous fistulas and in maintaining remission in patients with Crohn disease. Infliximab also leads to endoscopic and histologic remission. There is a trend toward benefit of subcutaneous recombinant interleukin-11 for active Crohn disease. Two pilot studies have shown that thalidomide may be of benefit in patients with refractory Crohn disease.
登录
查看更多内容
他克莫司（FK-506）治疗儿童暴发性结肠炎。
DOI：
10.1097/00005176-199610000-00023
发表时间：
1996
影响因子：
2.9
作者：
Bousvaros,A;Wang,A;Leichtner,AM
通讯作者：
Leichtner,AM
炎症性肠病中的血浆和直肠腺苷：甲氨蝶呤的作用。
影响因子：
4.9
作者：
Egan,LJ;Sandborn,WJ;Mays,DC;Tremaine,WJ;Lipsky,JJ
通讯作者：
Lipsky,JJ
影响因子：
29.4
作者：
Vasiliauskas, EA;Kam, LY;Targan, SR
通讯作者：
Targan, SR
影响因子：
29.4
作者：
Silverstein, MD;Loftus, EV;Zinsmeister, AR
通讯作者：
Zinsmeister, AR